Etanercept for Idiopathic Pneumonia Syndrome after HSCT

Etanercept (Enbrel) Administration for Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Gregory Yanik, Beth Hellerstedt, Joseph Custer, Raymond Hutchinson, Deborah Kwon, James L. M. Ferrara, Joseph Uberti, Kenneth R. Cooke

Biology of Blood and Marrow Transplantation 8:395-400 (2002)
© 2002 American Society for Blood and Marrow Transplantation

ABSTRACT:

Acute pulmonary dysfunction remains a frequent and severe complication of hematopoietic stem cell transplantation (SCT). Almost half of the pulmonary insults that occur in this setting are noninfectious in origin and are referred to as idiopathic pneumonia syndrome (IPS). In this series of 3 patients, etanercept (Enbrel; Immunex, Seattle, WA), a soluble, dimeric tumor necrosis factor α-binding protein, was administered to 3 consecutive pediatric allogeneic BMT recipients with IPS. The administration of etanercept, in combination with standard immunosuppressive therapy, was well tolerated and associated with significant improvements in pulmonary dysfunction within the first week of therapy. These data suggest that etanercept may represent a safe, non-cross-reactive, therapeutic option for patients with IPS and that clinical trials studying etanercept for this indication are warranted.

Download a PDF version of the full article

Copyright 1995-2010 - Carden Jennings Publishing Co., Ltd. All rights reserved. The material available at this site is for educational purposes only and is NOT intended for any diagnostic, clinically related, or other purpose. Carden Jennings Publishing Co., Ltd., assumes no responsibility for any use or misuse of this material and makes no warranty or representation of any kind with respect to the material available at this site.

Featured Resources Multiple Myeloma: A Practical Guide to Current Management BloodLine Image Atlas